You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

programmed cell death receptor 1 (PD-1)

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Locally Advanced Cervical Cancer Trial in Villejuif (Atezolizumab, Radiotherapy, Cisplatin)

Recruiting
  • Locally Advanced Cervical Cancer
  • Villejuif, Val De Marne, France
    Gustave Roussy
Feb 15, 2022

NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 18, 2022

Recurrent/Metastatic Gastric Cancer Trial in Seoul (Nivolumab, Paclitaxel)

Completed
  • Recurrent/Metastatic Gastric Cancer
  • Nivolumab, Paclitaxel
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Sep 9, 2022

NSCLC Trial in Marietta, Taichung City, Tainan (Sacituzumab Govitecan, Pembrolizumab)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Sacituzumab Govitecan
  • Pembrolizumab
  • Marietta, Georgia
  • +2 more
Jan 27, 2023

NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 18, 2022

Soluble Programmed Death-1 in Predicting Progression of

Recruiting
  • Nontuberculous Mycobacterial Lung Disease
    • Taipei, Taiwan
      National Taiwan University Hospital
    Jan 18, 2023

    Large B-cell Lymphoma Trial in Groningen (89Zr-atezolizumab PET-imaging)

    Recruiting
    • Large B-cell Lymphoma
    • 89Zr-atezolizumab PET-imaging
    • Groningen, Netherlands
      University Medical Center Groningen
    Jul 15, 2022

    Anti-Programmed Cell Death Protein 1 Immunotherapy in Head and

    Recruiting
    • Head and Neck Cancer
    • Strasbourg, France
      Institut de cancérologie Strasbourg Europe
    Apr 14, 2022

    Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1 Trial in Shanghai (Toripalimab (anti-programmed death-1 inhibitor),

    Recruiting
    • Oral Squamous Cell Carcinoma
    • +3 more
    • Toripalimab (anti-programmed death-1 inhibitor)
    • +4 more
    • Shanghai, Shanghai, China
      Ninth People's Hospital, Shanghai Jiao Tong University School of
    Oct 8, 2022

    Advanced Solid Tumors Trial in Australia (HLX20)

    Completed
    • Advanced Solid Tumors
    • Darlinghurst, New South Wales, Australia
    • +5 more
    Jun 1, 2022

    Urothelial Carcinoma Trial in Worldwide (Zilovertamab vedotin)

    Recruiting
    • Urothelial Carcinoma
    • Zilovertamab vedotin
    • Cleveland, Ohio
    • +11 more
    Jan 25, 2023

    Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guangzhou (bTAE-HAIC, Lenvatinib, Sintilimab)

    Not yet recruiting
    • Liver Diseases
    • +4 more
    • bTAE-HAIC
    • +2 more
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Sep 30, 2023

    Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guanzhou (bTAE-HAIC, Lenvatinib, Camrelizumab)

    Not yet recruiting
    • Liver Diseases
    • +4 more
    • bTAE-HAIC
    • +2 more
    • Guanzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Sep 24, 2023

    Tumor Trial in Chuo-Ku, Kashiwa (JNJ-63723283, Erdafitinib)

    Completed
    • Neoplasm
    • Chuo-Ku, Japan
    • +1 more
    Nov 3, 2022

    Lichen Planus Trial in Cairo (Skin Biopsy)

    Not yet recruiting
    • Lichen Planus
    • Skin Biopsy
    • Cairo, Egypt
      Cairo University
    May 14, 2021

    Tumors Trial in United States (Niraparib, Pembrolizumab, TSR-042 (Dostarlimab))

    Completed
    Has Results
    • Neoplasms
    • Whittier, Alaska
    • +15 more
    Aug 29, 2022

    PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer

    Recruiting
    • Immune Checkpoint Inhibitors
    • +9 more
    • Radiotherapy for targeted lesions and PD-1 antibody
    • Beijing, Beijing, China
      Lei Li
    Apr 1, 2022

    Bladder Cancer Trial in Korea, Republic of, Poland, United States (PF-07225570, sasanlimab)

    Recruiting
    • Bladder Cancer
    • New York, New York
    • +5 more
    Jun 28, 2022

    Rectal Cancer Stage, Oesophageal Cancer Trial in Vienna (CRT, SCPRT, CROSS Protocol)

    Not yet recruiting
    • Rectal Cancer Stage
    • Oesophageal Cancer
    • CRT
    • +3 more
    • Vienna, Austria
      Medical University of Vienna
    Mar 26, 2022

    Tumors Trial in Worldwide (Dostarlimab)

    Recruiting
    • Neoplasms
    • Dostarlimab
    • Birmingham, Alabama
    • +105 more
    Nov 17, 2022

    Donafenib Trial in Shanghai (Donafenib, PD-1, TACE)

    Recruiting
    • Donafenib
    • Donafenib, PD-1
    • TACE
    • Shanghai, Shanghai, China
      Zhongshan Hospital, Fudan University,
    Mar 4, 2022

    Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • BTK inhibitor
    • PD-1 inhibitor
    • Shanghai, China
      Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
    May 20, 2023

    Molecular Subtyping of Extensive Stage Small Cell Lung Cancer

    Recruiting
    • SCLC,Extensive Stage
    • PD-(L)1 antibody immunotherapy
    • Beijing, Beijing, China
      Peking University Cancer Hospital & Institute
    Jul 3, 2023

    Malignant Melanoma Trial (tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy)

    Withdrawn
    • Malignant Melanoma
    • tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy
    • (no location specified)
    Nov 12, 2021

    HLA-A2 Positive Cells Present, Refractory Melanoma Trial in Buffalo (Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1

    Recruiting
    • HLA-A2 Positive Cells Present
    • Refractory Melanoma
    • Alpha-type-1 Polarized Dendritic Cells
    • +5 more
    • Buffalo, New York
      Roswell Park Cancer Institute
    Dec 12, 2022